Hematology-Oncology Associates of NNJ, P.A.
Morristown, New Jersey, United States
Oncologist in Mountain Lakes, New Jersey
333 US-46, Mountain Lakes, NJ 07046
About Hematology-Oncology Associates of NNJ, P.A.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Hematology-Oncology Associates of NNJ, P.A.
During the past decade, Hematology-Oncology Associates of NNJ, P.A. conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 10 clinical trials were completed, i.e. on
average, 1000% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
2010-04-01
2012-01-01
Completed
26
Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)
2011-09-01
2015-05-01
Completed
54
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
2014-02-20
2021-12-23
Completed
85
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
2016-09-09
2020-12-15
Completed
681
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
2017-03-24
2024-08-15
Active, not recruiting
1,239
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
2018-06-06
2023-02-17
Terminated
1,054
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
2020-11-26
2029-03-30
Recruiting
865
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Hematology-Oncology Associates of NNJ, P.A." #1 sponsor was "Celgene" with 5 trials, followed by "US Oncology Research" with 4 trials
sponsored, "Amgen" with 2 trials sponsored, "Novartis Pharmaceuticals" with 2 trials sponsored and "Accelerated Community Oncology Research Network"
with 2 trials sponsored. Other sponsors include 0 different institutions and
companies that sponsored additional 10 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Hematology-Oncology Associates of NNJ, P.A."
#1 collaborator was "Sanofi" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 8 trials.
Clinical Trials Conditions at Hematology-Oncology Associates of NNJ, P.A.
According to Clinical.Site data, the most researched conditions in "Hematology-Oncology Associates of NNJ, P.A." are
"Breast Cancer" (3 trials), "Multiple Myeloma" (3 trials), "Advanced Breast Cancer" (1 trials), "Advanced Prostate Cancer" (1 trials) and "Androgen-independent Prostate Cancer" (1 trials). Many other conditions were trialed in "Hematology-Oncology Associates of NNJ, P.A." in a lesser frequency.
Clinical Trials Intervention Types at Hematology-Oncology Associates of NNJ, P.A.
Most popular intervention types in "Hematology-Oncology Associates of NNJ, P.A." are "Drug" (17 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (3 trials), "Bortezomib" (2 trials), "Dexamethasone" (2 trials), "Docetaxel" (2 trials) and "Lenalidomide" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Hematology-Oncology Associates of NNJ, P.A.
The vast majority of trials in "Hematology-Oncology Associates of NNJ, P.A." are
13 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.
Clinical Trials Status at Hematology-Oncology Associates of NNJ, P.A.
Currently, there are NaN active trials in "Hematology-Oncology Associates of NNJ, P.A.".
undefined are not yet recruiting,
undefined are recruiting,
2 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 14 completed trials in Hematology-Oncology Associates of NNJ, P.A.,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Hematology-Oncology Associates of NNJ, P.A., 1 "Phase 1"
clinical trials were conducted, 11 "Phase 2" clinical
trials and 6 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".